Literature DB >> 11078686

Determinants of the contractile properties in the embryonic chicken gizzard and aorta.

O Ogut1, F V Brozovich.   

Abstract

Smooth muscle is generally grouped into two classes of differing contractile properties. Tonic smooth muscles show slow rates of force activation and relaxation and slow speeds of shortening (V(max)) but force maintenance, whereas phasic smooth muscles show poor force maintenance but have fast V(max) and rapid rates of force activation and relaxation. We characterized the development of gizzard and aortic smooth muscle in embryonic chicks to identify the cellular determinants that define phasic (gizzard) and tonic (aortic) contractile properties. Early during development, tonic contractile properties are the default for both tissues. The gizzard develops phasic contractile properties between embryonic days (ED) 12 and 20, characterized primarily by rapid rates of force activation and relaxation compared with the aorta. The rapid rate of force activation correlates with expression of the acidic isoform of the 17-kDa essential myosin light chain (MLC(17a)). Previous data from in vitro motility assays (Rover AS, Frezon Y, and Trybus KM. J Muscle Res Cell Motil 18: 103-110, 1997) have postulated that myosin heavy chain (MHC) isoform expression is a determinant for V(max) in intact tissues. In the current study, differences in V(max) did not correlate with previously published differences in MHC or MLC(17a) isoforms. Rather, V(max) was increased with thiophosphorylation of the 20-kDa regulatory myosin light chain (MLC(20)) in the gizzard, suggesting that a significant internal load exists. Furthermore, V(max) in the gizzard increased during postnatal development without changes in MHC or MLC(17) isoforms. Although the rate of MLC(20) phosphorylation was similar at ED 20, the rate of MLC(20) dephosphorylation was significantly higher in the gizzard versus the aorta, correlating with expression of the M130 isoform of the myosin binding subunit in the myosin light chain phosphatase (MLCP) holoenzyme. These results indicate that unique MLCP and MLC(17) isoform expression marks the phasic contractile phenotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11078686     DOI: 10.1152/ajpcell.2000.279.6.C1722

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  19 in total

Review 1.  Vascular smooth muscle phenotypic diversity and function.

Authors:  Steven A Fisher
Journal:  Physiol Genomics       Date:  2010-08-24       Impact factor: 3.107

Review 2.  Myosin phosphatase isoforms as determinants of smooth muscle contractile function and calcium sensitivity of force production.

Authors:  Rachael P Dippold; Steven A Fisher
Journal:  Microcirculation       Date:  2014-04       Impact factor: 2.628

3.  Tra2β protein is required for tissue-specific splicing of a smooth muscle myosin phosphatase targeting subunit alternative exon.

Authors:  Kang Fu; Ylva Mende; Bhupal P Bhetwal; Salah Baker; Brian A Perrino; Brunhilde Wirth; Steven A Fisher
Journal:  J Biol Chem       Date:  2012-03-21       Impact factor: 5.157

4.  PHI-1 interacts with the catalytic subunit of myosin light chain phosphatase to produce a Ca(2+) independent increase in MLC(20) phosphorylation and force in avian smooth muscle.

Authors:  Amr El-Toukhy; Allison M Given; Ozgur Ogut; Frank V Brozovich
Journal:  FEBS Lett       Date:  2006-09-27       Impact factor: 4.124

5.  Competition of PTB with TIA proteins for binding to a U-rich cis-element determines tissue-specific splicing of the myosin phosphatase targeting subunit 1.

Authors:  Supriya Shukla; Fabienne Del Gatto-Konczak; Richard Breathnach; Steven A Fisher
Journal:  RNA       Date:  2005-09-21       Impact factor: 4.942

6.  Tra2beta as a novel mediator of vascular smooth muscle diversification.

Authors:  Supriya Shukla; Steven A Fisher
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

7.  Altered contractile phenotypes of intestinal smooth muscle in mice deficient in myosin phosphatase target subunit 1.

Authors:  Wei-Qi He; Yan-Ning Qiao; Ya-Jing Peng; Juan-Min Zha; Cheng-Hai Zhang; Chen Chen; Cai-Ping Chen; Pei Wang; Xiao Yang; Chao-Jun Li; Kristine E Kamm; James T Stull; Min-Sheng Zhu
Journal:  Gastroenterology       Date:  2013-03-13       Impact factor: 22.682

8.  Transgenic overexpression of ribonucleotide reductase improves cardiac performance.

Authors:  Sarah G Nowakowski; Stephen C Kolwicz; Frederick Steven Korte; Zhaoxiong Luo; Jacqueline N Robinson-Hamm; Jennifer L Page; Frank Brozovich; Robert S Weiss; Rong Tian; Charles E Murry; Michael Regnier
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

9.  A signal transduction pathway model prototype II: Application to Ca2+-calmodulin signaling and myosin light chain phosphorylation.

Authors:  Thomas J Lukas
Journal:  Biophys J       Date:  2004-09       Impact factor: 4.033

Review 10.  The potential role of MLC phosphatase and MAPK signalling in the pathogenesis of vascular dysfunction in heart failure.

Authors:  Ozgur Ogut; Frank V Brozovich
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.